Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants

Guillain–Barré syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidate...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-01, Vol.9 (1), p.1077-1077, Article 1077
Main Authors: Park, Soo Jin, Kim, Jong Kuk, Kim, Hyun-Hwi, Yoon, Byeol-A., Ji, Dong Yoon, Lee, Chang-Wan, Kim, Ho Jin, Kim, Kyoung Heon, Shin, Ha Young, Park, Sung Jean, Lee, Do Yup
Format: Article
Language:English
Subjects:
631/250/38
631/553/2714
692/53/2421
Bayesian analysis
Biomarkers
Central nervous system
Cerebrospinal fluid
Correlation analysis
Demyelination
Guillain-Barre syndrome
Humanities and Social Sciences
Lipid metabolism
Lipids
Metabolism
Metabolites
Metabolomics
multidisciplinary
Nervous system
Peripheral neuropathy
Polyneuropathy
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Guillain–Barré syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidated yet. In current study, integrative metabolomic and lipidomic profiles were acquisitioned from cerebrospinal fluid samples of 86 GBS from three variants and 20 disease controls. And the data were systematically compared to our previous result on inflammatory demyelination disorders of central nervous system (IDDs) and healthy controls. Primary metabolite profiles revealed unique metabolic traits in which 9 and 7 compounds were specifically changed in GBS and IDD, respectively. Next, the biomarker panel with 10 primary metabolites showed a fairly good discrimination power among 3 GBS subtypes, healthy controls, and disease controls (AUCs ranged 0.849–0.999). The robustness of the biomarker panel was vigorously validated by multi-step statistical evaluation. Subsequent lipidomics revealed GBS variant-specific alteration where the significant elevations of lyso-phosphatidylcholines and sphingomyelins were unique to AIDP (acute inflammatory demyelinating polyneuropathy) and AMAN (acute motor axonal neuropathy), respectively. And metabolome-wide multivariate correlation analysis identified potential clinical association between GBS disability scale (Hughes score) and CSF lipids (monoacylglycerols, and sphingomyelins). Finally, Bayesian network analysis of covarianced structures of primary metabolites and lipids proposed metabolic hub and potential biochemical linkage associated with the pathology.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-37572-w